[C-peptide residual secretion makes difference on type 1 diabetes management?].
Type 1 diabetes is a chronic disease characterized by progressive destruction of the pancreatic beta cells, what leads to insulin deficiency and hyperglycemia. However, a significant secretory function may persist for long periods in a few patients, what is clinically evident through the detection of serum C peptide. This phenomenon might reduce the risk of chronic complications, severe hypoglycemias and allow easier metabolic control. It is possible that these advantages are caused, at least partially, by C peptide itself, acting directly in its target tissues.
Rodacki
Melanie
M
Serviço de Nutrologia e Diabetes, Universidade Federal do Rio de Janeiro RJ, Brasil. mrodacki@hucff.ufrj.br
Milech
Adolpho
A
Oliveira
José Egídio Paulo de
JE
D000293:Adolescent; D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000097:blood; D001786:Blood Glucose / Q000378:metabolism; D002096:C-Peptide / Q000097:blood* / Q000378:metabolism; D002648:Child; D002675:Child, Preschool; D002908:Chronic Disease; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000150:complications / Q000628:therapy*; D005260:Female; D006801:Humans; D007003:Hypoglycemia / Q000378:metabolism / Q000503:physiopathology; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000378:metabolism; D007328:Insulin / Q000008:administration & dosage / Q000378:metabolism; D000078790:Insulin Secretion; D050417:Insulin-Secreting Cells / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D055815:Young Adult
D015415:Biomarkers; D001786:Blood Glucose; D002096:C-Peptide; D007004:Hypoglycemic Agents; D007328:Insulin